Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.32 |
| ▸ | USP1 | O94782 | 2/20 | 0.31 |
| ▸ | BRD1 | O95696 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.30 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566540 | 0.87 | BRD4 (0.37) | SLC22A12ERN1MAPK10 | |
| SCHEMBL24309792 | 0.87 | BRD4 (0.37) | SLC22A12ERN1MAPK10 | |
| SCHEMBL26808359 | 0.84 | GPR39 (0.35) | USP1BRD1BRPF1 | |
| SCHEMBL26808363 | 0.84 | ALDH1A1 (0.35) | USP1 | |
| SCHEMBL26806772 | 0.79 | TSHR (0.35) | SCN9A | |
| SCHEMBL26808361 | 0.79 | LTB4R (0.31) | USP1 | |
| SCHEMBL29566663 | 0.78 | SCN1A (0.32) | USP1 | |
| SCHEMBL24309702 | 0.78 | SCN1A (0.32) | USP1 | |
| SCHEMBL29567059 | 0.78 | USP1 (0.31) | USP1 | |
| SCHEMBL24309340 | 0.78 | USP1 (0.31) | USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CRHR1 4483/4885SCN9A 385/4885USP1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.